Interruption of Mesalamine and Reduction of the Blood Concentration of the Active Metabolites of Azathioprine: Possible Causes of Ulcerative Colitis Relapse
暂无分享,去创建一个
A. Ventura | S. Martelossi | G. Decorti | G. Stocco | N. Malusà | F. Bartoli | Sara Marino
[1] C. Mulder,et al. Dose-Dependent Influence of 5-Aminosalicylates on Thiopurine Metabolism , 2007, The American Journal of Gastroenterology.
[2] A. Andriulli,et al. Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy , 2007, Alimentary pharmacology & therapeutics.
[3] M. Schwab,et al. Adherence to thiopurine treatment in out‐patients with Crohn’s disease , 2007, Alimentary pharmacology & therapeutics.
[4] B. Xia,et al. N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease. , 2007, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[5] H. Herfarth,et al. Monitoring of Thiopurine Methyltransferase Activity in Postsurgical Patients With Crohn's Disease During 1 Year of Treatment With Azathioprine or Mesalazine , 2007, Therapeutic drug monitoring.
[6] M. Montico,et al. Glutathione‐S‐transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease , 2007, Inflammatory bowel diseases.
[7] U. Klotz,et al. Thiopurine Treatment in Inflammatory Bowel Disease , 2007, Clinical pharmacokinetics.
[8] R. Gearry,et al. Thiopurine Treatment in Inflammatory Bowel Disease , 2007, Clinical pharmacokinetics.
[9] A. Timmer,et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. , 2007, The Cochrane database of systematic reviews.
[10] A. Bousvaros,et al. 5‐Aminosalicylate therapy is associated with higher 6‐thioguanine levels in adults and children with inflammatory bowel disease in remission on 6‐mercaptopurine or azathioprine , 2006, Inflammatory bowel diseases.
[11] P. Lionetti,et al. TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease. , 2005, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[12] U. Klotz,et al. Effects of aminosalicylates on thiopurine S‐methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease , 2005, Alimentary pharmacology & therapeutics.
[13] C. Lewis,et al. Mutation in the ITPA Gene Predicts Intolerance to Azathioprine , 2003, Nucleosides, nucleotides & nucleic acids.
[14] Richard M Weinshilboum,et al. N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis , 2002, American Journal of Gastroenterology.
[15] S. Cucchiara,et al. Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey , 2002, Alimentary pharmacology & therapeutics.
[16] R. Weinshilboum,et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide , 2001, Gut.
[17] D. Present. Interaction of 6-mercaptopurine and azathioprine with 5-aminosalicylic acid agents. , 2000, Gastroenterology.
[18] B. Bonaz,et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. , 2000, Gastroenterology.
[19] R. Boulieu,et al. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. , 1998, Clinical chemistry.
[20] R. Weinshilboum,et al. Olsalazine and 6‐mercaptopurine‐related bone marrow suppression: A possible drug‐drug interaction , 1997, Clinical pharmacology and therapeutics.